Avancées en Recherche & Développement

Poursuite du développement du portefeuille de produits COVID-19pour répondre aux besoins du marché Paris, France et Camberley, Royaume-Uni – 16 novembre 2020 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait un état des lieux de l’avancée de ses activités R&D. http://novacyt.com/wp-content/uploads/2020/11/Novacyt-RD-Update-16-11-2020-FRENCH.pdf

Visit Page

R&D Update

Continued expansion of COVID-19 product portfolio to address unmet market needs Paris, France and Camberley, UK – 16 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&D update. http://novacyt.com/wp-content/uploads/2020/11/Novacyt-RD-Update-16-11-20-ENGLISH.pdf

Visit Page

Director/PDMR Shareholding

Paris, France and Camberley, UK – 13 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 13 November 2020, James McCarthy (PDMR), a corporate consultant, acquired 10,000 ordinary shares of €1/15 each in the Company at an average price of £8.953

Visit Page